Evercore ISI Issues Positive Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its target price increased by Evercore ISI from $155.00 to $175.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Several other research firms also recently weighed in on RGEN. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a research note on Wednesday, October 1st. Barclays increased their price target on Repligen from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. HSBC started coverage on Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 price target for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Repligen in a research note on Saturday, September 27th. Finally, Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price target for the company in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $169.62.

Repligen Stock Down 2.8%

Shares of NASDAQ:RGEN opened at $145.93 on Tuesday. The company has a market capitalization of $8.21 billion, a PE ratio of -583.70, a price-to-earnings-growth ratio of 2.77 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The business has a fifty day moving average price of $123.40 and a two-hundred day moving average price of $125.50. Repligen has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus acquired 1,800 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the acquisition, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. purchased a new stake in shares of Repligen in the 3rd quarter valued at about $5,423,000. Moody National Bank Trust Division purchased a new stake in shares of Repligen in the 3rd quarter valued at about $212,000. Texas Permanent School Fund Corp raised its holdings in shares of Repligen by 36.2% in the 2nd quarter. Texas Permanent School Fund Corp now owns 25,141 shares of the biotechnology company’s stock valued at $3,127,000 after acquiring an additional 6,688 shares in the last quarter. Squarepoint Ops LLC raised its holdings in shares of Repligen by 49.7% in the 2nd quarter. Squarepoint Ops LLC now owns 73,792 shares of the biotechnology company’s stock valued at $9,178,000 after acquiring an additional 24,510 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Repligen in the 2nd quarter valued at about $353,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.